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ABSTRACT
Major efforts are underway to systematically de®ne
the somatic and germline genetic variations
causally associated with disease. Genome-wide
genetic analysis of actual clinical samples is, how-
ever, limited by the paucity of genomic DNA avail-
able. Here we have tested the ®delity and genome
representation of f29 polymerase-based genome
ampli®cation (f29MDA) using direct sequencing
and high density oligonucleotide arrays probing
>10 000 SNP alleles. Genome representation was
comprehensive and estimated to be 99.82% com-
plete, although six regions encompassing a
maximum of 5.62 Mb failed to amplify. There was
no degradation in the accuracy of SNP genotyping
and, in direct sequencing experiments sampling
500 000 bp, the estimated error rate (9.5 3 10±6) was
the same as in paired unampli®ed samples. The
detection of cancer-associated loss of heterozygos-
ity and copy number changes, including homozy-
gous deletion and gene ampli®cation, were similarly
robust. These results suggest that f29MDA yields
high ®delity, near-complete genome representation
suitable for high resolution genetic analysis.
INTRODUCTION
Understanding the genomic alterations of disease-derived
cells is of vital importance for the development of more
rational diagnostics and treatment strategies. In principle, the
completed sequence of the human genome allows for the
interrogation of virtually every single base for variations
between the canonical and disease genome sequences.
However, genetic analysis of clinical samples is often limited,
in practice, by the amount of genomic DNA available. New
technologies allowing in vitro production of numerous copies
of the entire genome are currently available. However, the
extent to which such methods result in a representative copy of
the initial genome and the ®delity with which such represen-
tative copies are produced remains largely uncharacterized.
Whole genome ampli®cation by multiple displacement
ampli®cation is based on the use of f29 DNA polymerase and
random primers (henceforth referred to as f29MDA) (1±4).
f29 polymerase combines high processivity with a strand
displacement ability leading to the synthesis of DNA
fragments >70 kb (5) and favoring uniform representation of
sequences. In addition, the enzyme possesses 3¢®5¢ exonu-
clease activity resulting in error rates thought to be between
10±5 and 10±6 (6).
In this study, we have used f29MDA to amplify genomic
DNA from both normal and cancer cells. We then tested the
accuracy and genome-wide coverage of f29MDA through
both direct sequencing of ~500 000 bp of DNA and the use of
high density oligonucleotide arrays interrogating >10 000
single nucleotide polymorphisms (SNPs). Genome-wide
ampli®cation achieved an estimated 99.82% coverage of the
human genome. SNP call concordance was comparable to that
of unampli®ed replicates and, in the context of large-scale
exon resequencing, highly accurate sequence data were
obtained from f29MDA samples when compared to samples
ampli®ed by standard methods. Finally, our ability to detect
several types of chromosomal aberrations, including loss of
heterozygosity (LOH), homozygous deletions and gene amp-
li®cation remained robust compared to non-ampli®ed sam-
ples. In summary, our results show that f29MDA affords
highly accurate and comprehensive whole genome ampli®ca-
tion suitable for high resolution genetic analysis.
*To whom correspondence should be addressed at: Dana-Farber Cancer Institute, D720C, 44 Binney Street, Boston, MA 02115, USA. Tel: +1 617 632 4750;
Fax: +1 617 632 5417; Email: william_sellers@dfci.harvard.edu
Nucleic Acids Research, 2004, Vol.32, No.9 e71
DOI: 10.1093/nar/gnh069
Nucleic Acids Research, Vol.32 No.9 ã Oxford University Press 2004; all rights reserved
  Published online May 18, 2004MATERIALS AND METHODS
DNA samples
Genomic DNA samples from cell lines were obtained from
ATCC (Manassas, VA). Of the 16 samples used, six were
breast cancer cell/normal pairs, namely cell lines HCC1008
(renamed HCC1007 for consistency), HCC1143, HCC1599,
HCC1937, HCC2218 and HCC38 and their normal counter-
parts generated by EBV-induced transformation of peripheral
blood lymphocytes obtained from the same patients
(HCC1007 BL, HCC1143 BL, HCC1599 BL, HCC1937 BL,
HCC2218 BL and HCC38 BL). Samples HCC2157 BL and
HCC1954 BL were unmatched. Two normal reference DNA
sets from blood samples were also obtained from Affymetrix
(Santa Clara, CA). For exon resequencing experiments
genomic DNA from 20 samples of lung adenocarcinoma
was used. DNA was quanti®ed using a PicoGreenâ dsDNA
quantitation kit (Molecular Probes Inc., Eugene, OR).
f29 polymerase multiple strand displacement whole
genome ampli®cation
Whole genome ampli®cation reagents (REPLI-gÔ 625S;
Molecular Staging Inc., New Haven, CT) were used as
follows. Brie¯y, 10 ng template DNA was mixed with 43
master mix (containing the reaction buffer and hexamer
primers) and the DNA polymerase in a 50 ml ®nal volume
reaction. Completed reactions were transferred to a 96-well
plate and incubated for 16 h at 30°C, followed by incubation at
65°C for 3 min to inactivate the enzyme. For ®ve samples
(HCC1007BL, HCC1007, HCC1143BL, HCC1143 and
HCC1599BL), template DNA was denatured using alkaline
denaturation prior to the f29MDA reaction (version 2
f29MDA). In all cases, 10 mg ampli®ed DNA was puri®ed
using a QIAquick PCR puri®cation kit (Qiagen Inc., Valencia,
CA). Puri®ed DNA was quanti®ed and 250 ng was used for
SNP array analysis and 5 ng for PCR followed by sequencing.
Single nucleotide polymorphism array experiments
10K Mapping Arrays and hybridization reagents were
obtained from Affymetrix (7,8). Aliquots of 250 ng genomic
or whole genome ampli®cation DNA was restricted with XbaI.
A single double-stranded linker was ligated to the XbaI
fragments using T4 DNA ligase. XbaI fragments were then
ampli®ed by single primer PCR as per the manufacturer's
protocol. PCR products were puri®ed from free primers and
nucleotides by differential precipitation in 2-propanol/sodium
perchlorate. The PCR products were quanti®ed spectro-
photometrically and assayed for the appropriate size distribu-
tion on a DNA analyzer (Agilent 2100 Bioanalyzer). The
puri®ed PCR products were fragmented with DNase I and the
resulting DNA was labeled with a single biotin at each free
3¢-OH using terminal deoxynucleotidyl transferase and a
dideoxy biotinylated nucleoside triphosphate. The bio-
tinylated fragments were added to a hybridization solution
[123 MES (1.22 M), 100% DMSO, 503 Denhardt's solution,
0.5 M EDTA, 10 mg/ml herring sperm DNA, 3 nM Oligo B2,
1 mg/ml human Cot-1, 1% Tween-20, 5 M TMACL]
containing a biotinylated control oligonucleotide (for quality
control) and then hybridized to a 10K SNP microarray chip
overnight at 48°C. The arrays were then washed six times with
non-stringent buffer A (63 SSPE, 0.01% Tween-20) and
stringent buffer B (0.63 SSPE, 0.01% Tween-20). Bound
DNA was then detected by incubation with streptavidin
followed by biotinylated anti-streptavidin, followed by
phycoerythrin-conjugated streptavidin (SAPE). Bound ¯uor-
escent antibody was detected using a confocal laser scanner
(570 nm) and the positions and intensities of the ¯uorescence
emissions were captured.
Single nucleotide polymorphism data visualization and
analysis
dChipSNP (9,10), a bioinformatics platform developed for
SNP array data analysis, was used to automate the process of
making LOH calls based on paired normal/tumor SNP calls
and displaying the SNP data according to their chromosomal
locations, along with cytogenetic band information. Figures
1B and 3B and C were generated based on `Chromosome
View' in dChipSNP. The SNP call rates of unampli®ed
samples were compared to those of the paired f29MDA
samples using the one sample Wilcoxon rank sum test. The
SNP or LOH call concordance rate between two samples was
calculated as the proportion of concordant markers among all
markers excluding those in which either one or both of the two
samples was NO_CALL. We used the two sample Wilcoxon
rank sum test to compare the SNP call concordance rate
between unampli®ed samples and the two types of f29MDA
samples (obtained from non-denatured and denatured DNA,
respectively) to the concordance rate between unampli®ed
replicates and also to compare the SNP call concordance rates
between the two types of f29MDA samples. To assess the
quality of f29MDA on the entire genome, all the arrays were
®rst normalized using the invariant set method and then for
each SNP marker a signal intensity index was calculated using
a model-based approach (11). The fold changes in the signal
intensity index between unampli®ed samples and f29MDA
samples were calculated for all SNP markers and statistical
signi®cance was assessed using a permutation test with
multiple comparison adjustment by the maxT procedure (12).
Copy number analysis
Based on the signal intensities, the copy number of each SNP
locus in cancer cell lines samples was estimated by hidden
Markov model analysis of the signal intensity variation along
each chromosome, compared to a set of normal references
(13). In addition to the unampli®ed normal samples described
above, over 50 additional samples from normal tissue were
included as unampli®ed normal references (generously pro-
vided by E.Hochberg and J.Ritz) to improve the accuracy of
copy number estimates. For the f29MDA DNA samples,
f29MDA DNA obtained from immortalized lymphocytes
(described above) was used as normal references. Copy
number estimates were binned in the categories 0, 1, 2, 3, 4
and >4 before calculating copy number discordance rates.
PCR and sequencing
One hundred tyrosine kinase exons and ¯anking intronic
sequences were ampli®ed using speci®c primers in a 384-well
format nested PCR set-up (J. G. Paez, J. C. Lee, M. Meverson
and W. R. Sellars, in preparation). The nested primers were
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ampli®ed and unampli®ed DNA. PCR products were puri®ed
using SPRI (solid phase reversible immobilization) chemistry
followed by bidirectional dye terminator ¯uorescent sequen-
cing with universal M13 primers. Sequencing fragments were
detected via capillary electrophoresis using an ABI Prism
Figure 1. Genome coverage following whole genome ampli®cation. (A) The SNP call rate before and after whole genome ampli®cation. Probes were
prepared from 250 ng DNA from samples of breast cancer cell line or paired normal cell line DNA either before (unampli®ed) or after (f29MDA)
ampli®cation and hybridized to Affymetrix 10K SNP arrays. In addition, 14 samples were ampli®ed without denaturation prior to whole genome
ampli®cation, while ®ve samples were ampli®ed after denaturation (as indicated). (B) Regions with loss of representation after f29MDA. For each indicated
region, the speci®c SNP allele hybridization intensity normalized on a scale of 0 (absent and white) to 6 (red) is shown for unampli®ed or ampli®ed samples.
Each row represents a single SNP allele, while each column represents a single DNA sample. Columns 1±5 correspond to denatured DNA samples
(HCC1007BL, HCC1007, HCC1143BL, HCC1143 and HCC1599BL). (C) The absence of ampli®cation of a region in the chromosome cytoband 6p25.3.
Using dChip-Signal, the mean signal intensity for each SNP allele on the 10K array was compared between samples before (left) and after (right) whole
genome ampli®cation. Signal intensity is shown normalized on a scale of 0 (white) to 6 (red). An enlargement of this region is shown in the middle panel.
The right panel indicates the calls for each speci®c SNP allele where white is no call, yellow is AB, blue is BB and red is AA. The region indicated by the
dotted line shows absent or incorrect calls in samples after MDA, corresponding to the region where signal loss was detected in dChip-Signal. Columns 1±5
correspond to denatured DNA samples.
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PCR and sequencing was performed at Agencourt Bioscience
Corp. (Beverly, MA).
Sequence data analysis
Forty DNA samples consisting of 20 generated by f29MDA
and 20 corresponding unampli®ed matched DNA were
sequenced against 100 amplicons. In all, 4000 forward (F)
and 4000 reverse (R) chromatogram reads (2000 sets) were
analyzed in batch by Mutation Surveyor (Soft Genetics Inc.
Version 2.03, release 9/25/2003). High quality sequence
variations found in both the forward and reverse directions
were exported into a ¯at text ®le for comparison between
f29MDA and unampli®ed DNA variation calls. A Perl script
was written to analyze the text ®les and data in which any of
the four possible reads (f29MDA F&R, unampli®ed F&R) did
not pass the quality standards for Mutation Surveyor analyses
were omitted. Filtering the data resulted in 1295 of the original
2000 sets of reads passing, representing ~500 000 bases
analyzed (F&R = 1 base). To analyze the sequencing data
using the Neighborhood Quality Standard (NQS) (14,15),
pair-wise alignments for each unampli®ed/f29MDA sample
pair were generated for each amplicon and differences were
detected using the NQS. Brie¯y, a base met NQS if the Phred
quality (16) was >30 and the 5 bases on each side had Phred
quality scores >25. Sample pairs with fewer than 50 NQS
bases were discarded. In samples potentially containing
deletions, average quality from neighboring bases was used
as a surrogate for base quality. The number of passing sample
pairs (>50 NQS bases compared) was 1585, leading to a total
of 404 335 NQS bases (F&R = 1 base).
RESULTS
Genome representation after f29 polymerase-based
whole genome ampli®cation
Genomic DNA from seven breast cancer cell lines and seven
EBV-immortalized lymphoblastoid cell lines was used for
these studies. Twelve of these samples represent six pairs
comprising a cancer-derived cell line and a lymphoblastoid
cell line representing the paired normal genome. Aliquots of
10 ng of each genomic DNA sample were subjected to
f29MDA, yielding an average of 25 mg total DNA/sample. In
addition, genomic DNA from ®ve samples was denatured by
treatment with alkali prior to f29MDA. To ascertain the extent
to which f29MDA resulted in whole genome representation,
we determined the rate of detection for ~10 000 SNPs alleles
in each DNA sample, using high density oligonucleotide
arrays. Here, 250 ng f29MDA DNA or unampli®ed DNA was
used to prepare probes for the Affymetrix 10K SNP array.
High quality array data was obtained on all samples as judged
by the performance of the spiked controls. As a ®rst measure
of genome representation we compared the number of SNPs
successfully detected or called (the call rate) in the f29MDA
samples versus unampli®ed samples by pair-wise comparison
(Fig. 1A). While all f29MDA samples performed acceptably,
in samples prepared by f29MDA without a preceding
denaturation step the mean call rate was 88.92%, compared
to a mean of 92.45% in the unampli®ed samples. The call rate
improved substantially with denaturing of genomic DNA prior
to f29MDA, such that the call rates were similar between
f29MDA and unampli®ed samples (92.06 versus 92.93%, P =
0.24).
We next determined whether this small decrease in the
mean call rate re¯ected random loss of genomic representation
differing in each f29MDA sample preparation or alternatively
re¯ected non-random loss of ampli®cation of speci®c regions
of the genome. Recent data from our group has shown that the
oligonucleotide SNP arrays can be used not only for the robust
speci®cation of allele calls, but can also detect copy number
changes (13). Thus, as a second approach to the question of
genome representation after f29MDA, we normalized oligo-
nucleotide signal intensity across all arrays using the invariant
probe set method (11) and determined whether speci®c
regions of the genome were under-represented in producing
hybridizing fragments, as indicated by consistent loss of the
hybridization signal. Here, the mean signal intensity for each
SNP allele in the ampli®ed samples was compared to the mean
signal intensity of the unampli®ed samples by plotting the log2
ratio of the mean f29MDA to unampli®ed signal (as shown for
chromosome 6 in Fig. 1C). Regions of statistically signi®cant
signal loss were then sought. Fourteen regions of consistent
signal loss were detected in the f29MDA ampli®ed samples
(Table 1). Conversely, no regions of loss were found in
unampli®ed samples when compared to the ampli®ed samples.
When the speci®c SNP alleles in each region were examined
in detail, six regions (1q42, 4q35, 6p25, 7q36, 10q26 and
18p11) showed both signi®cantly reduced oligonucleotide
signal intensity and consistent no-call designations in the
f29MDA samples (Fig. 1B and Table 1, shaded in gray). An
example of one such region located on chromosome 6p25.3 is
shown in Figure 1C, where the mean signal intensity of
f29MDA and unampli®ed samples, as well as the speci®c
allele calls, are shown. The remaining eight regions had low
signal intensity, suggesting inadequate ampli®cation, how-
ever, there was apparently suf®cient ampli®cation to allow
accurate detection of the speci®c SNP alleles. The six regions
of low intensity and poor SNP calls represent a maximum of
5.64 Mb (measured from the ®rst ¯anking retained SNP
markers). For the currently assembled human genome size of
3070 Mb (17) these data give an estimated genome coverage
of (3070 ± 5.64 Mb/3070 Mb) 3 100 = 99.82%.
These regions of loss are not physically constrained to
particular chromosomal segments such as telomeres, thus we
examined each region to determine whether there were any
obvious clues as to why such regions might be more dif®cult
to amplify. While each region contains repetitive elements of
the LINE, SINE and MER1 families, it is unclear whether this
bears causally on the lack of ampli®cation for these small
regions.
Fidelity of whole genome ampli®cation for detecting
SNP alleles
In order to ascertain whether f29MDA gives robust SNP allele
calls when used in a large-scale SNP genotyping application,
we next determined the SNP call concordance between
f29MDA ampli®ed and unampli®ed pairs. Here, only SNPs
giving `calls' in both the unampli®ed and the f29MDA
samples were considered. To assess the experimental vari-
ability, SNP concordance was measured in 10 pairs of
replicate samples. Concordance was 99.85% among paired
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f29MDA samples were compared to the unampli®ed samples
and 99.80% (P = 0.12) when alkaline denatured f29MDA
samples were compared to unampli®ed samples (Fig. 2A±C).
Examination of the discrepancies between non-denatured
f29MDA and unampli®ed samples showed that 63% were
heterozygotes called as homozygotes. Approximately 30% of
all calls were heterozygotes and hence the heterozygote drop-
out rate is ~0.73% for this method (data not shown). It is
thought that the inclusion of an alkaline denaturation step may
reduce stochastic effects and serve to ensure even priming of
maternal and paternal alleles. Indeed, the heterozygote drop-
out rate decreased by 24-fold from 0.73 to <0.03% with
inclusion of the alkaline denaturation step. In no case were
homozygote conversions detected.
As the rate of discordant calls found in the denatured
samples was nearly identical to that found in the replicate data,
we conclude that under these conditions the SNP error rate
after f29MDA is within the experimental error for this assay
and thus the estimated upper bound of the f29MDA error rate
is <0.2%. These data indicate that highly reliable SNP
genotyping can be obtained after f29MDA genome ampli®-
cation.
Direct sequencing comparison
In order to test more robustly the ®delity of f29MDA, 20
samples of DNA obtained from lung adenocarcinoma were
subjected to f29MDA. Next, all 20 f29MDA ampli®ed and
the corresponding unampli®ed genomic DNA samples were
used in nested PCR ampli®cation reactions to generate
sequencing templates for 100 tyrosine kinase exons. All
resulting amplicons were then used in ¯uorescent dye
terminator sequencing reactions with standard M13 forward
and reverse primers. A total of 1295 paired f29MDA and
unampli®ed sequencing reads were available for analysis by
Mutation Surveyor, representing nearly 500 000 paired bases
for each method. Single direction sequences where the
opposite read was not available were excluded. In this dataset,
variants from the canonical sequence were detected using
Mutation Surveyor followed by manual review. There were
234 variants detected by both methods, four variants detected
in unampli®ed samples not found in the f29MDA samples and
®ve variants found in the f29MDA samples that were not
found in the unampli®ed samples (Table 2). From these data
we estimate that the error rate of PCR-based ampli®cation and
sequencing is 7.6 3 10±6 and that of f29MDA followed by
PCR-based sequencing is 9.5 3 10±6. These error rates are not
different statistically.
We also approached the question of ®delity using the NQS
(14,15) to detect homozygous changes between unampli®ed
and ampli®ed samples. Because NQS excludes heterozygous
base calls, it produces a lower bound on the discrepancy rate
between ampli®ed and unampli®ed sample pairs. In 404 335
bases that passed the NQS quality criteria, ®ve differences
were detected: four substitutions and one two-base insertion.
The overall concordance rate was therefore 1 ± (5/404335) =
0.999985. In all ®ve discrepancies, the f29MDA ampli®ed
sample differed from the canonical sequence. Illustrative of
two of these variations are the dinucleotide insertion and the
homozygous base pair substitution shown in Figure 3. Thus a
lower bound for error introduced by f29MDA estimated by
NQS is 1.24 3 10±5.
These error rates are relatively low in the context of PCR-
based sequencing efforts, nonetheless, the possibility of a few
f29MDA-induced alterations including homozygous changes
detected by the NQS method indicates that sequencing
recon®rmation of candidate variants from unampli®ed DNA
samples or from independently ampli®ed samples may be
warranted, as is currently the case for alterations detected in
PCR ampli®ed samples.
Detection of large-scale genetic alterations after whole
genome ampli®cation
Methods for robust whole genome ampli®cation may enable
genome-wide analysis of the somatic genetic alterations from
samples that are limited to a few hundred cells. Samples where
there is an obvious need for such ampli®cation include needle
aspiration biopsy specimens, samples of preneoplastic lesions,
circulating cancer cells and foci of cancer isolated by laser
capture microdissection (LCM). Cancer genomes harbor
numerous large-scale genetic alterations, including trans-
locations, homozygous deletions, chromosomal and gene
ampli®cations and regions undergoing LOH resulting from
either hemizygous deletion or gene conversion. To determine
whether such alterations are reproducibly detected after
f29MDA, the SNP array data for six paired cancer/normal
samples were analyzed for LOH and for copy number
differences (e.g. ampli®cations and deletions) before and
after f29MDA.
To determine the LOH concordance rate, each SNP allele
found to be heterozygous in the normal and undergoing LOH
(reduction to a homozygous state) in the cancer was compared
in ampli®ed and unampli®ed pairs. Here, the mean pair-wise
concordance rate was 99.58% and was highly consistent
across all six pairs (Fig. 4A). Regions of LOH typically
encompass many such heterozygote SNPs, thus this degree of
LOH concordance leads to highly reproducible LOH maps, as
shown for chromosome 4 (Fig. 4B).
Table 1. Under-represented regions after whole genome ampli®cation
Cytobanda Locationb Markerc SNP calld (%)
1q42.3 231.859845±232.716009 273247C 0
2p25.3 2.981319±3.533432 510038A 100
4q35.2 189.005358±189.512271 53705A 0
6p25.3 1.308549±1.308710 (min) 47914C, 47913A 0
1.267150±1.461644 (max)
7p13 43.671625±45.002746 446257A 100
7q36.3 154.928147±155.709859 696854A 0
8p11.1 40.228919±46.972292 1135786A 100
9q34.11 122.379760±125.318769 423667A 100
10q26.3 132.676552-qter 725725A 0
16q22.1 66.320884±69.686706 56839C 100
18p11.21 11.601378±12.539851 64448A 0
20p11.23 20.264205±20.826382 48858G 100
20q13.33 60.531791±62.575257 108798A 100
22q13.1 37.019787±39.869701 242417C 100
aCytoband is based on the hg15 golden path assembly (NCBI build 33)
(http://genome.ucsc.edu/).
bChromosomal location in Mb.
cSNP probe set name.
dFor the six f29MDA samples, six (100%) or zero (0%) SNP calls were
obtained.
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deletion events and copy number changes are robustly
detected using signal intensity measures derived from the
SNP oligonucleotide probe sets (13). We therefore compared
the signal intensity for each SNP locus for the test samples to a
set of normal controls. A hidden Markov model was
constructed to estimate the most likely copy number for
each locus in the test sample along each chromosome (11). To
determine whether homozygous deletions are likewise
detected after f29MDA, we applied this method to the data
from our cell lines. In unampli®ed samples, 11 homozygous
deletions were detected. Eleven of 11 were also detected in the
samples after f29MDA. Representative examples of homo-
zygous deletions on chromosomes 3 and 9 are shown in
Figure 4C (upper panels). The deletion at 3p15 in the HCC 38
cell line has been reported previously (18).
To determine the concordance of copy number estimates
between f29MDA and unampli®ed samples, the pair-wise
Figure 2. SNP allele concordance. (A) SNP allele concordance between pairs of f29MDA ampli®ed and unampli®ed samples (black and dark gray). (B) SNP
allele concordance between pairs of unampli®ed replicates (light gray). (C) Mean concordance in the same pair-wise comparisons as shown in (A) and (B).
Table 2. Direct sequence comparison
No. of variations Error (310±6) Concordance
Both 234
Unampli®ed 4 7.6 0.9999924
Whole genome
ampli®ed
5 9.5 0.9999905
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sample or f29MDA sample was compared. The mean signal
intensity concordance in replicate samples was R = 0.896 6
0.0276 with R values ranging from 0.788 to 0.943, while the
mean signal intensity concordance of the f29MDA and
unampli®ed sample pairs was 0.894 6 0.0459, with a range
from 0.835 to 0.925. Representative concordance plots are
shown in Figure 4D.
To further ascertain the range of variation in genome
representation, signal intensity ratios were calculated where,
at each SNP position, the intensity in the unampli®ed sample
was divided by either a replicate pair or by the corresponding
f29MDA ampli®ed sample (Fig. 5A and B). In addition, the
mean intensity ratio and the 25th and 75th percentile
boundaries for the intensity ratios for all markers were
determined and plotted separately (Fig. 5E). The comparison
of unampli®ed replicates versus f29MDA shows a slight
systematic under-representation as the mean intensity ratio is
<1 for the comparison of unampli®ed samples to ampli®ed
samples (see Fig. 5E). In addition, there is a clear structure
within the f29MDA plots not apparent in the comparison of
replicated unampli®ed samples (compare Fig. 5B and A). The
nature of this additional structure within these data is not clear,
however, it appears to be topological. This structure does not
appear to contribute to the overall variation as there is no
difference between replicates and f29MDA ampli®ed samples
with respect to the extent of overall variation (Fig. 5E). The
addition of a denaturing step prior to ampli®cation appears to
have little or no effect in this structure nor was there an
alteration in variation (Fig. 5C and D).
For the purposes of estimation of relative copy number in
cancer samples, standardization using f29MDA ampli®ed
non-tumor samples as the copy-normal controls appears to
overcome these problems. To evaluate how well copy number
estimates were preserved after f29MDA, copy number
estimates were binned in six categories: 0, 1, 2, 3, 4 and >4.
Using these binned estimates, the copy number concordance
for unampli®ed f29MDA pairs was 87%, comparable to that
obtained for unampli®ed replicates. The majority of copy
number discrepancies were single copy disagreements, while
<1% were discrepant by more than one copy number
difference (Table 3). This allowed us to compare the detection
of regions of copy number ampli®cation between f29MDA
and unampli®ed samples. In this set of cell lines eight regions
of high copy number ampli®cation were identi®ed in the
unampli®ed cancer samples and were con®rmed by quantita-
tive real-time PCR. All eight were also detected in f29MDA
sampleswithcomparablecopynumberestimates(seeTable4).
DISCUSSION
Large-scale sequencing, SNP genotyping and cancer genomic
studies will, over the next few years, allow de®nition of the
germline and somatic genetic alterations causally linked to
oncogenesis. Currently, such studies require substantial
quantities of high quality DNA. Indeed, a number of efforts
directed at cancer somatic genetics have been initiated with
cell lines because of the quantity of DNA required (19).
Techniques such as f29MDA that allow the robust ampli®-
cation of entire genomes from a limited number of genome
copies hold the potential to allow large-scale studies to be
conducted from primary sample sources. Sources of interest
include not only surgically resected specimens, but also
genomes isolated from needle biopsies, buccal swabs, circu-
lating cancer cells, LCM cells and ultimately from single
tumor cells. In order for ampli®ed DNA to be utilized in high
resolution genetic analysis, uniform and accurate genome-
wide representation are required.
Genome coverage
Here we report the ®rst genome-scale survey to determine the
extent of coverage by f29MDA using high density SNP
arrays. The results presented herein rely on sampling >10 000
SNP markers spaced across the genome with a mean
intermarker distance of 210 kb. The 10K SNP array, however,
contains no probes for markers on 13p, 14p, 15p, 21p, 22p or
Y and poor representation of centromeric and telomeric
regions of other chromosomes. This array representation
further varies between chromosomes, being sparsest for
chromosomes 17, 19, 20 and 22. The median intermarker
distance, which leaves out these areas, is 105 kb. Thus, while
this sampling was not perfectly distributed across the genome,
it is likely that the genome coverage results reported herein
can be extrapolated to these uncovered regions. In this study,
Figure 3. Rare homozygous sequence variations in f29MDA samples. DNA sequence traces for unampli®ed (upper) and f29MDA (lower) samples showing
a homozygous 2 bp (CT) insertion and a homozygous C®T substitution (white arrows) detected by NQS analysis. All samples were non-denatured.
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and paired unampli®ed samples. Overall, f29MDA samples
rendered call rates comparable to, but slightly lower than
(although not reaching statistical signi®cance), those of
unampli®ed DNA. While genome coverage was estimated to
be 99.82%, we identi®ed six regions that were consistently
non-represented in whole genome ampli®cation DNA. In
addition, eight additional regions were under-represented.
Figure 4. Detection of LOH, homozygous deletions and gene ampli®cation after f29MDA. (A) Concordance of LOH detection in cancer/normal samples
before and after f29MDA. HCC1007 and HCC1143 tumor/normal pairs and HCC1599 BL were denatured prior to ampli®cation. (B) LOH map of
chromosome 4 representative of whole genome LOH maps from six breast cancer/normal pairs. Informative SNP loci showing retention of heterozygosity are
shown in yellow, uninformative SNPs (i.e. homozygous or no-call in normal) in gray and SNP alleles undergoing LOH in blue. The ®rst two columns
correspond to denatured tumor/normal DNA samples. For the third column, only the normal DNA was denatured. The remaining three columns correspond to
all non-denatured tumor/normal pairs. (C) Detection of homozygous deletions and gene ampli®cation. SNP signal intensity is displayed as rows where inten-
sity is normalized on a scale of 0 (white) to 6 (dark red). The upper panels show two representative regions of homozygous deletion on chromosomes 3 and 9
in six breast cancer/normal pairs. The ®rst two columns correspond to tumor samples denatured prior ampli®cation. The lower panel shows representative
regions of ampli®cation on chromosomes 12 and 19. Only the individual cancer cell line samples showing gain are shown. Copy number loss or gain is
indicated by the blue line in the gray box. HCC1143 was denatured prior ampli®cation whereas HCC1599 was not. (D) Representative SNP hybridization
intensity concordance plots. Hybridization intensities from unampli®ed DNA are plotted against corresponding intensities from a second replicate
hybridization of unampli®ed DNA (top) and from whole genome ampli®ed DNA (bottom). The best ®t linear correlation is represented in blue. Correlation
coef®cients (top left corners), representing signal intensity concordance rates, are similar in both cases. These data are representative examples of all
pair-wise MDA/unampli®ed and unampli®ed/replicate comparisons examined in this manner. The mean R values for these comparisons are presented in
the text.
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regions, signal intensity was consistently lower across all
samples, so this reduction in representation might impair
other genetic analysis techniques, e.g. gene copy number
determination. For most applications this extent of genome
coverage will suf®ce, however, if speci®c susceptibility genes
or susceptibility loci fall within such under- or unampli®ed
regions, important genetic contributors to disease might be
Figure 5. Variation in genome ampli®cation after f29MDA. All the arrays were normalized using the common baseline array HCC1937 BL_250303 by the
invariant set method. Then the model-based signal intensities for all SNPs were calculated by the PM/MM difference model. The log2 signal ratios of all
SNPs were calculated and plotted separately for each of the: (A) 11 unampli®ed replicate pairs; (B)1 4f29MDA/unampli®ed pairs; (C) ®ve denatured
f29MDA/unampli®ed pairs; (D) nine non-denatured f29MDA/unampli®ed pairs. The three plots were adjusted to have the same scale for better comparison,
thus a few extreme outliers are not shown in some plots. (E) The median ratio for each of the sets of comparisons as well as the range of values encompassing
the 25±75th percentile values are shown.
Table 3. Distribution of copy number differences
Percent concordant Percent with copy number differences of
12 3 4
Unampli®ed replicatesa 88 12 0.03
Unampli®ed vs MDAb 87 13 0.2 0.03 0.001
Copy numbers were estimated at each SNP locus by comparing the signal intensities observed in each sample to the signal intensities observed in a set of
germline DNA samples (see Materials and Methods).
aComparison between repeated runs of unampli®ed DNA (six samples).
bComparison between whole genome ampli®ed and corresponding unampli®ed DNA (18 samples).
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f29MDA (4,20,21) interrogated a total of 100 loci distributed
across all chromosomes and noted robust coverage of these
speci®c loci, though under-representation of LINE1 elements
was also noted. Whether this contributes to the failure to
amplify the six regions detected in our studies is not yet clear.
Application to large-scale SNP genotyping efforts
In this survey of 10 000 SNP genotypes there was high
concordance between f29MDA and unampli®ed DNA. This is
in keeping with previous reports on a limited number of SNPs
where concordance was 100 (4,20) and 99.7% (21). In our
study there was no statistical difference between f29MDA and
unampli®ed samples in SNP call concordance. Indeed,
previous data as well as our own support the notion that
preservation of SNP heterozygotes after f29MDA ampli®ca-
tion is quite robust. Based on our data on genome represen-
tation, if SNPs fall within regions that are poorly ampli®ed
there will be a loss of detection for these SNPs. Thus, as higher
density SNP maps become available, the number of indeter-
minate SNP calls (or `missing SNP data') may grow. The
overall SNP error rate after f29MDA is within that expected
from experimental error of this assay, therefore, we conclude
that f29MDA DNA can be used for genome-wide SNP
mapping studies. Preliminary results using f29MDA to
perform similar genotyping studies on DNA obtained after
LCM demonstrate call and concordance rates similar to those
obtained with cell line DNA (data not shown).
Application to high throughput sequencing efforts
The ®delity of a PCR-based sequencing pipeline is constrained
by the least accurate step. In our case, the limiting step is PCR
ampli®cation using a proofreading-de®cient Taq polymerase.
Direct sequencing of a pool of PCR products tends to
minimize, although not eliminate, random errors introduced
by the polymerase during PCR. Thus, the quality of initial
template DNA introduced into the PCR reaction is critical.
f29 polymerase has been reported to possess an intrinsic
proofreading activity ensuring accurate DNA replication (6).
To investigate the ®delity of MDA in our system, we
resequenced 100 tyrosine kinase amplicons in 20 pairs of
whole genome ampli®cation or unampli®ed samples.
Although, we observed virtually identical error rates (~1 3
10±5) for both f29MDA and unampli®ed samples, we did ®nd
a small excess of homozygous changes in f29MDA samples.
This may be due to the fact that the resequencing study was
done without the denaturing step prior to MDA. Thus, in
keeping with our SNP concordance results, we hypothesize
that the inclusion of a denaturation step before ampli®cation
may partially correct the allele bias. The rate of error
introduced by f29MDA appears to be quite low, although,
nonetheless, con®rmational sequencing of candidate variants
from unampli®ed DNA samples or from independently
ampli®ed samples is warranted.
Application to the detection of LOH and copy number
changes
Large-scale genetic alterations, including changes in gene
copy number such as deletions and ampli®cation or LOH, are
hallmarks of the perturbed cancer cell genome (22). As
expected from the very high SNP concordance rate, the
concordance of LOH between f29MDA and unampli®ed
cancer samples is also very high (99.58%), allowing the
construction of robust LOH maps (23) for the study of the
genetic alterations of cancer cell genomes.
With respect to copy number alterations, our results indicate
that MDA results in a change in the copy number structure but
doesnotincreasethemeanvariationinsignalintensity(Fig.5).
While this manuscript was in preparation, Lage et al. (24)
reported signi®cant over- and under-representation of clusters
of yeast ORFs evaluated by array-CGH. Most of the under-
represented loci map to the ends of yeast chromosomes.
Similar results were obtained on human cDNA arrays.
Whether these alterations are similar to those seen in our
data remains to be determined. Additional studies using
quantitative PCR have shown that loci representation in
f29MDA DNA, as a percentage relative to an unampli®ed
genomic DNA standard, ranged between 50 and 300%, a
maximum 6-fold bias between any two loci (20). Despite these
changes in genome representation, for the purpose of detecting
copy number changes in cancer samples we found that
normalization against f29MDA non-tumor samples led to
copy number estimates that were relatively well preserved
after f29MDA, with a copy number concordance of 87%
Table 4. Regions of high level genome ampli®cation detected in ampli®ed or unampli®ed cancer cell line genomes
Cytobanda Candidate geneb Cell line Quantitative numberc Copy no. predictiond
Unampli®ed f29MDA
11q13.3 CCND1 HCC1143 25.44 7 6
12q14.3 DYRK2 HCC1143 10.05 9 6
19q12 CCNE1 HCC1599 13.48 7 6
8q24.1 MYC HCC38 3.35 3 3
8q24.1 MYC HCC1937 3.69 3 4
8q24.1 MYC HCC1143 4.04 4 3
8q24.1 MYC HCC1599 4.69 4 4
8q24.1 MYC HCC2218 3.70 4 4
aCytoband is based on the hg15 golden path assembly (NCBI build 33) (http://genome.ucsc.edu/).
bThe gene is either within or very close to the predicted region.
cRepresents copy number estimated by quantitative real-time PCR.
dCopy numbers as predicted by hidden Markov modeling from SNP array intensity data analysis of unampli®ed and MDA DNA. Only cell line HCC1143
was denatured prior to ampli®cation.
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number variation was typically con®ned to within a single
copy number unit and variation outside of that bound was
unusual. There are three reasons that may explain high copy
number concordance rates in our data despite the signal
intensity variations seen here and in other studies. First, the
SNP probes tend to be under-represented in telomeric and
centromeric regions, where increased copy number variability
was noted. Second, many of the signal intensity changes
between unampli®ed and f29MDA ampli®ed samples appear
to be systematic rather than randomerrorsand are corrected by
normalizing against a f29MDA ampli®ed control. This
®nding was also noted by Lage et al. in their work with
MDA using the Bst polymerase (24). Finally, signal intensity
changes in individual loci do not necessarily translate into
copy number errors when applying our method for determin-
ing copy number based on hidden Markov models. This
method utilizes the signal intensities of neighboring loci when
estimating the copy number for a given locus, therefore
averaging over random errors. Importantly, cancer-associated
high level ampli®cation and homozygous deletions were
readily and reliably detected in f29MDA samples.
In summary, our results show that f29MDA DNA provides
a highly accurate and comprehensive representation of the
unampli®ed genome, suitable for high resolution genetic
analysis, including SNP genotyping, gene copy number
detection and direct sequencing. Thus, it is now reasonable
to expect that such technologies may be widely applied on a
genome scale to primary clinical samples.
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